Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

BO-653. Chugai.

Charles Q Meng¹

¹AtheroGenics Inc, 8995 Westside Parkway, Alpharetta, GA 30004, USA. Cmeng@atherogenics.com

Current Opinion in Investigational Drugs (London, England : 2000)

|May 9, 2003

Summary

This summary is machine-generated.

BO-653, an antioxidant, is being developed for atherosclerosis and restenosis prevention. Clinical trials in the US and Japan are evaluating its potential in treating these cardiovascular conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Carboxylated, heteroaryl-substituted chalcones as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.

Journal of medicinal chemistry·2007

Same author

Atherosclerosis is an inflammatory disorder after all.

Current topics in medicinal chemistry·2006

Same author

AGIX-4207 [2-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetic acid], a novel antioxidant and anti-inflammatory compound: cellular and biochemical characterization of antioxidant activity and inhibition of redox-sensitive inflammatory gene expression.

The Journal of pharmacology and experimental therapeutics·2005

Same author

Inflammation in atherosclerosis: new opportunities for drug discovery.

Mini reviews in medicinal chemistry·2005

Same author

Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.

Journal of medicinal chemistry·2004

Same author

A new era in atherosclerosis drug discovery.

Expert review of cardiovascular therapy·2004

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

Area of Science:

Cardiovascular pharmacology
Drug development
Antioxidant research

Background:

Atherosclerosis is a major cardiovascular disease.
Restenosis after angioplasty poses a significant clinical challenge.
Antioxidants show potential in managing vascular conditions.

Purpose of the Study:

To evaluate the efficacy of BO-653 in preventing restenosis.
To assess the safety and tolerability of BO-653 in clinical trials.
To explore the therapeutic potential of BO-653 for atherosclerosis.

Main Methods:

Phase II clinical trials for restenosis prevention post-angioplasty in the US.
Phase I clinical trials for restenosis in Japan.
Pharmacological studies on antioxidant properties of BO-653.

Related Experiment Videos

Main Results:

BO-653 is under active clinical investigation for cardiovascular applications.
Trial data will determine the compound's efficacy and safety profile.
Ongoing research focuses on BO-653's role in vascular health.

Conclusions:

BO-653 demonstrates potential as a therapeutic agent for cardiovascular diseases.
Further clinical evaluation is necessary to establish its role in treatment.
The development of BO-653 highlights ongoing efforts in cardiovascular drug discovery.